PDS Biotechnology (NASDAQ:PDSB) Releases Earnings Results, Beats Estimates By $0.02 EPS

PDS Biotechnology (NASDAQ:PDSB) issued its earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, FiscalAI reports.

Here are the key takeaways from PDS Biotechnology’s conference call:

• PDS Biotechnology amended VERSATILE-003 to use progression-free survival as an interim primary endpoint, which management believes could speed an accelerated approval path and shorten the trial’s duration.
• The company said the amended design also reduces costs by lowering the trial size from about 350 patients to 250 and changing the randomization ratio to 1:1:1.
• Management highlighted continued momentum in PDS0101, saying the therapy remains a differentiated late-stage option in HPV-16 positive head and neck cancer because it is subcutaneous and requires only five doses.
• The company reported encouraging updates from its PDS01ADC program in both colorectal and prostate cancer, including published biomarker data and early clinical results that support broader immuno-oncology potential.
• First-quarter 2026 results showed a net loss of $7.3 million versus $8.5 million a year ago, with cash of $21.7 million at quarter-end and lower operating expenses year over year.

PDS Biotechnology Stock Down 5.6%

NASDAQ PDSB traded down $0.08 on Friday, reaching $1.35. The company had a trading volume of 848,149 shares, compared to its average volume of 793,018. The stock has a market capitalization of $73.44 million, a P/E ratio of -2.02 and a beta of 1.51. The company’s fifty day moving average is $0.90 and its 200 day moving average is $0.86. PDS Biotechnology has a 52-week low of $0.51 and a 52-week high of $1.92. The company has a quick ratio of 2.98, a current ratio of 2.98 and a debt-to-equity ratio of 1.27.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, PDS Biotechnology has a consensus rating of “Hold” and a consensus price target of $9.00.

Institutional Investors Weigh In On PDS Biotechnology

Large investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in shares of PDS Biotechnology during the 2nd quarter valued at $92,000. Commonwealth Equity Services LLC increased its position in shares of PDS Biotechnology by 117.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the last quarter. Armistice Capital LLC purchased a new stake in shares of PDS Biotechnology during the 4th quarter valued at $2,182,000. Geode Capital Management LLC increased its position in shares of PDS Biotechnology by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after purchasing an additional 38,399 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of PDS Biotechnology by 116.1% during the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares during the last quarter. 26.84% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.